Multi-institutional observational study for the efficacy and safety of Carfilzomib for multiple myeloma in Kyoto Clinical Hematology Study Group (KOTOSG)
Not Applicable
Completed
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000025108
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who reject the enrollment in the study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of Carfilzomib-containing therapy for multiple myeloma
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Carfilzomib in treating multiple myeloma as studied in KOTOSG-CFZ?
How does Carfilzomib compare to other proteasome inhibitors like Bortezomib in multiple myeloma treatment outcomes?
What biomarkers correlate with Carfilzomib response in relapsed/refractory multiple myeloma patients in the KOTOSG-CFZ study?
What are the most common adverse events associated with Carfilzomib in the KOTOSG observational trial and how are they managed?
Are there combination therapies involving Carfilzomib that show improved efficacy in multiple myeloma compared to monotherapy?